The role of biologic agents in the management of common shoulder pathologies: current state and future directions.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31585784.
- Also identified by DOI 10.1016/j.jse.2019.07.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The field of orthopedic surgery has seen a rapid increase in the use of various biologic agents for the treatment of common musculoskeletal injuries. Most biologic agents attempt to harness or mimic naturally occurring growth factors, cytokines, and anti-inflammatory mediators to improve tissue healing and recovery. The most commonly used biologic agents are platelet-rich plasma and cells derived from bone marrow aspirate and adipose tissue. These agents have become increasingly popular despite a relative dearth of clinical data to support their use. Much confusion exists among patients and physicians in determining the role of these agents in treating common shoulder pathologies, such as glenohumeral osteoarthritis, rotator cuff tears, and tendinopathy. This article reviews the basic science and clinical evidence for the most commonly used biologic agents in the management of common shoulder pathology.
Medical subject headings
- Biological Factors
- Joint Diseases
- Shoulder Injuries
- Shoulder Joint
Anatomy
- shoulder